HCC Member

Hans R. Widlund, PhD

Brigham And Women's Hospital

Academic Titles
Assistant Professor, Dermatology, Harvard Medical School
Research Program Affiliation
Member, Melanoma
Research Abstract

Our work serves to identify molecular drivers that can inform therapeutic opportunity and to define useful prognostic biomarkers that collectively may help patients towards optimal melanoma treatment. Specifically, using orthogonal analyses of tumor cell metabolism, paralleled with clinical outcome correlates, we currently characterize inherent cues that steer tumor cell vulnerabilities towards each intrinsic; BRAF(V600E)-targeted, and extrinsic; immune checkpoint inhibition agents.